Table 2.
Study characteristic |
Crude OR (95% Cl)
|
Adjusted OR (95% Cl)*
|
||||
---|---|---|---|---|---|---|
<$20 000/QALY | <$50 000/QALY | <$100 000/QALY | <$20 000/QALY | <$50 000/QALY | <$100 000/QALY | |
Publication year | ||||||
1976-91 | 1.6 (0.98 to 2.7) | 1.4 (0.80 to 2.4) | 1.2 (0.67 to 2.3) | 1.6 (0.96 to 2.7) | 1.3 (0.76 to 2.3) | 1.2 (0.61 to 2.2) |
1992-6 | 1.3 (0.94 to 1.9) | 1.4 (0.93 to 2.3) | 1.1 (0.68 to 1.6) | 1.3 (0.87 to 1.8) | 1.3 (0.87 to 1.9) | 1.0 (0.64 to 1.6) |
1997-2001 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
Journal impact factor† | ||||||
<2 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
2-4 | 0.62 (0.42 to 0.91) | 0.62 (0.41 to 0.94) | 0.59 (0.38 to 0.94) | 0.75 (0.50 to 1.1) | 0.82 (0.53 to 1.3) | 0.77 (0.47 to 1.2) |
>4 | 0.60 (0.42 to 0.86) | 0.56 (0.38 to 0.82) | 0.83 (0.53 to 1.3) | 0.95 (0.63 to 1.4) | 0.81 (0.52 to 1.3) | 1.1 (0.66 to 1.9) |
Disease category | ||||||
Cardiovascular | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
Endocrine | 1.3 (0.68 to 2.6) | 1.2 (0.58 to 2.5) | 1.3 (0.58 to 3.0) | 1.2 (0.56 to 2.4) | 1.1 (0.52 to 2.3) | 1.2 (0.53 to 2.7) |
Infectious | 1.1 (0.66 to 1.7) | 0.79 (0.48 to 1.3) | 0.74 (0.43 to 1.3) | 1.0 (0.64 to 1.7) | 0.75 (0.44 to 1.3) | 0.71 (0.39 to 1.3) |
Musculoskeletal | 1.4 (0.60 to 3.3) | 1.3 (0.51 to 3.1) | 1.4 (0.50 to 3.7) | 1.1 (0.43 to 2.7) | 0.89 (0.34 to 2.3) | 1.1 (0.37 to 3.1) |
Neoplastic | 0.91 (0.56 to 1.5) | 0.79 (0.46 to 1.3) | 0.77 (0.42 to 1.4) | 0.78 (0.47 to 1.3) | 0.64 (0.37 to 1.1) | 0.69 (0.36 to 1.3) |
Neurological/psychiatric | 0.76 (0.40 to 1.5) | 0.78 (0.40 to 1.5)) | 0.66 (0.31 to 1.4) | 0.75 (0.39 to 1.4) | 0.70 (0.34 to 1.4) | 0.61 (0.27 to 1.4) |
Other | 1.2 (0.75 to 1.8) | 0.67 (0.42 to 1.1) | 0.52 (0.31 to 0.88) | 1.0 (0.63 to 1.6) | 0.53 (0.31 to 0.88) | 0.49 (0.27 to 0.86) |
Study funding source‡ | ||||||
Non-industry | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
Industry | 2.2 (1.4 to 3.4) | 3.5 (2.0 to 6.1) | 3.4 (1.6 to 7.0) | 2.1 (1.3 to 3.3) | 3.2 (1.8 to 5.7) | 3.3 (1.6 to 6.8) |
Not specified | 1.3 (0.95 to 1.9) | 1.5 (1.1 to 2.2) | 1.4 (0.93 to 2.1) | 1.3 (0.89 to 1.8) | 1.5 (1.0 to 2.1) | 1.5 (0.97 to 2.2) |
Region of study | ||||||
Europe | 0.50 (0.28 to 0.89) | 0.43 (0.21 to 0.87) | 0.46 (0.21 to 1.0) | 0.59 (0.33 to 1.1) | 0.42 (0.21 to 0.86) | 0.43 (0.19 to 0.96) |
United States | 0.35 (0.21 to 0.57) | 0.29 (0.16 to 0.55) | 0.33 (0.16 to 0.66) | 0.44 (0.26 to 0.76) | 0.35 (0.18 to 0.67) | 0.33 (0.16 to 0.68) |
Other§ | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
Methodological quality¶ | ||||||
1.0-4.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
4.5-5.0 | 0.92 (0.64 to 1.3) | 0.95 (0.64 to 1.4) | 0.96 (0.62 to 1.5) | 1.0 (0.70 to 1.5) | 1.1 (0.70 to 1.6) | 1.0 (0.63 to 1.6) |
5.5-7.0 | 0.48 (0.33 to 0.70) | 0.57 (0.39 to 0.83) | 0.82 (0.52 to 1.3) | 0.58 (0.37 to 0.91) | 0.72 (0.45 to 1.2) | 0.90 (0.51 to 1.6) |
QALY, quality adjusted life year.
Adjusted for all other study characteristics.
Impact factor in the year before publication.
Funding by a pharmaceutical or medical device manufacturer.
Canada 41 (59%), Australia 18 (26%), Japan 2 (3%), New Zealand 2 (3%), South Africa 2 (3%), other 5 (7%).
Mean score from two reviewers.